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ABSTRACT
Introduction: Diabetic kidney disease (DKD) is the leading worldwide cause of end-
stage renal disease. The current recommendation is to screen for DKD by evaluating 
estimated glomerular filtration rate (eGFR) and measuring urinary albumin (UA) 
levels in a spot sample. The aim of this study was to evaluate the availability of UA 
measurement in Southern Brazilian laboratories.
Methods: A cross-sectional study was conducted to assess the routine use of UA in 
all laboratories registered in the State Pharmacy Council of Rio Grande do Sul, the 
southernmost state of Brazil. Data was collected by mail, e-mail, telephone, or personal 
interview. A sample size of at least 384 laboratories was necessary to achieve 5% 
precision at a 95% confidence level based on a fixed proportion of 0.5.
Results: Eight hundred and eighty laboratories currently registered in the state were 
invited to participate in the study; 548 (62%) answered the technical specification 
questionnaire. Only 306 (55%) of the 548 surveyed laboratories performed UA 
measurements. The laboratories were also required to provide the number of UA 
measurements performed per day, which ranged from less than one per week to 65 
per day.
Conclusion: The availability of UA measurements is undesirably low in Southern 
Brazil. This demonstrates the urgent need to increase the availability of this important 
test. It also reveals the gap between the current guidelines and the awareness about 
them among health care professionals.
Keywords: Diabetes kidney disease; diabetes mellitus; urinary albumin measurement; 
albuminuria; diabetic nephropathy
Diabetic kidney disease (DKD) is a serious microvascular complication of 
diabetes mellitus (DM), and the leading worldwide cause of end-stage renal 
disease1,2. The early detection of DKD allows for the use of strategies to halt 
its development or at least delay the progression of the disease3.
The current recommendation is to screen for DKD by measuring albumin 
levels in a spot urine collection, which accurately replaces 24-h collections, 
and by evaluating serum creatinine to estimate the glomerular filtration rate 
(eGFR). International and national guidelines advocate the performance of 
these tests in patients with type 1 diabetes after 5 years of the disease, and 
in all patients with type 2 DM starting at diagnosis4-6.
Unfortunately, albumin measurement procedures are not readily available 
in all clinical laboratories, especially in low-income countries. The aim of this 
study was to evaluate the availability of urinary albumin (UA) measurement 
in Southern Brazilian laboratories.
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METHODS
A survey was conducted to assess the routine 
use of renal function tests (UA and eGFR) in all 
laboratories registered in the State Pharmacy Council 
of Rio Grande do Sul, the southernmost state of 
Brazil. The state area is divided geographically into 
north and south regions7,8. Our results regarding the 
prevalence and reporting of eGFR testing have been 
previously published9.
This cross-sectional study started in July 2010 
and ended in July 2012. The investigation was 
approved by the Research Ethics Committee of our 
institution (protocol no. 10-0129), and each laboratory 
agreed to participate in the survey. The variable of 
interest was assessed by a technical specification 
survey including the following questions: 1) Is urinary 
albumin measured in your laboratory? 2) How many 
albumin measurements are performed daily? Data 
was collected by mail, e-mail, telephone, or personal 
interview.
A sample size of at least 384 laboratories was 
necessary to achieve 5% precision at a 95% confidence 
level based on a fixed proportion of 0.510. Statistical 
analyses were performed using the Predictive Analytics 
Software (PASW) package, version 20.0 (Statistical 
Package for the Social Sciences-Professional Statistics 
TM, Chicago, IL, USA).
RESULTS
Of the 880 laboratories registered in the state 
and invited to participate in the survey, 548 (62%) 
answered the technical specification questionnaire 
(figure 1). Of these, 403/648 (62%) were located in 
the northern region and 145/232 (64%) were located 
in the southern region of the state, thus ensuring the 
geographic representativeness of the data collected 
(figure 2).
Of the 548 respondents, 306 (55%) reported to 
perform UA measurement at their laboratories. Of the 
242 that did not measure UA, 56 sent the samples 
to be analyzed by an external laboratory. Thirty-four 
(6.9%) laboratories informed that they were only 
able to measure total protein concentration in urine.
The laboratories were also asked about the number 
of albumin measurement procedures performed per 
day, which ranged from less than one per week to 
65 per day.
DISCUSSION
Our study revealed that only half of the Southern 
Brazilian laboratories included in this study perform UA 
measurements. This alarming low rate is in contrast 
with the efforts of national and international DM care 
guidelines, which recommend the use of annual UA 
measurements to identify the presence of DKD4-6. 
Poor accessibility to kidney function assessment 
has also been reported in other regions in the world. 
Only 33% of patients in North Africa11 and 30% of 
individuals with type 2 DM in some regions of Finland 
perform urinary albumin tests on a yearly basis12. A 
recent systematic review evaluating the standards 
for DM care in Central and South America found that 
the prevalence of annual albuminuria screenings 
among patients with DM ranged from 1-80%, which 
reveals the presence of significant heterogeneity in 
patient care, with important barriers to healthcare13. 
Fortunately, some countries have much higher 
albuminuria screening rates, such as Israel, where 
approximately 72.6% of patients undergo annual 
screening tests11. In the United States, the first national 
initiative to establish a set of measures to assess 
patients with DM has been developed recently and 
it includes HbA1c, low-density lipoprotein, and blood 
pressure measurements, in addition to eye and renal 
examinations14. Therefore, a similar national task 
force in this regard is clearly necessary in our country.
Albuminuria is a very simple and low-cost procedure, 
hardly costing more than 2-3 dollars. It is easily 
Figure 1: Flowchart of the participating laboratories.
Figure 2: Map of Rio Grande do Sul with laboratories in 
the North and South regions.
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adaptable to automatization, which only requires the 
use of routine equipment, readily available in most 
ordinary laboratories. Furthermore, the validity of the 
use of a spot urine albumin sample to detect DKD 
is worldwide recognized, replacing the cumbersome 
24-h urine collection to screen for elevated albumin 
levels, additionally simplifying the procedure5. At most, 
a second collection may be necessary to confirm the 
diagnosis due to the high coefficient of variation of this 
measurement15. Therefore, there appears to be no 
justifiable reason for laboratories not to perform UA 
measurement procedures. In addition, governmental 
policies should implement task forces to ensure that 
this test is accessible to every patient. We found 
that some laboratories did not perform UA because 
the test is seldom requested (data not shown). In 
this regard, we identify a serious gap between the 
guidelines and physicians’ awareness about them, 
thus showing the need for further education and 
training of health care staff.
Albuminuria was first suggested as a marker 
of kidney disease in 1969, when Harry Keen and 
colleagues demonstrated a slight increase in UA 
excretion – microalbuminuria – during a glucose test in 
patients with DM, using a sensitive radioimmunoassay 
method16. Since then, UA assessments have been 
extensively used as a tool to predict advanced kidney 
disease, cardiovascular events, and increased 
mortality17. However, the reliability of UA as a 
diagnostic tool for DKD has been questioned by 
some authors, since only one-third of the patients with 
increased UA excretion progress to more advanced 
stages of the disease3. Furthermore, approximately 
25% of patients with DM have normal UA, and the 
diagnosis of DKD is based on reduced GFR levels 
only18. Nevertheless, even though other new kidney 
disease biomarkers have been investigated, none of 
them demonstrated better diagnostic performance 
than albuminuria in screening for DKD19. Recent 
investigations with proteomics approach suggest 
that this technique, in a near future, might be able 
to identify diabetes renal involvement earlier20. As 
for now, UA has been the most extensively studied 
DKD marker, and is arguably the best method to 
screen for the condition.
The latest DKD guidelines recommend replacing 
the terms micro- and macroalbuminuria with the 
term “increased albuminuria”, since it appears to 
convey in a more accurate manner the idea of a 
continuum of risk. This idea is corroborated by our 
own previous findings, as well as by those of other 
studies, which have demonstrated that even “high-
normal” albuminuria may be predictive of advanced 
kidney disease and mortality1,21.
Surprisingly, it was only recently that a candidate 
liquid chromatography-mass spectrometry (LC-MS/
MS) was developed as a reference measurement 
procedure to assess UA22. Another reference 
measurement procedure has been developed in the 
Mayo Clinic Renal Function Laboratory, using trypsin 
digestion of whole urine followed by LC-MS/MS23. 
This initiative will allow for the standardization and 
harmonization of UA measurements.
A limitation of our survey is that it applies only 
to the southernmost region of Brazil. The wealthy 
Southeast region (where São Paulo and Rio de 
Janeiro are located) could perhaps return better 
results. On the other hand, in the Northern region 
of Brazil, the poorest region of the country, an even 
worse scenario could be probably found.
In conclusion, in our region, the availability of 
urinary albumin measurements is undesirably low, 
indicating an urgent need to increase the availability 
of this simple, albeit important, procedure.
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